Tapentadol

Results: 167



#Item
121Alzheimer’s Medications:

Alzheimer’s Medications:

Add to Reading List

Source URL: dvha.vermont.gov

Language: English - Date: 2013-06-05 08:06:32
122Alzheimer’s Medications:

Alzheimer’s Medications:

Add to Reading List

Source URL: dvha.vermont.gov

Language: English - Date: 2013-05-21 21:10:49
123HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FOSRENOL safely and effectively. See full prescribing information for FOSRENOL. FOSRENOL (lanthanum carbonate) Chewa

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FOSRENOL safely and effectively. See full prescribing information for FOSRENOL. FOSRENOL (lanthanum carbonate) Chewa

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-09-07 15:08:27
124CDER New Molecular Entity (NME) Drug and New Biologic Approvals for Calendar Year 2008 Updated through December 31, 2008 NME New Drug Application (NDA) Approvals: Application Type

CDER New Molecular Entity (NME) Drug and New Biologic Approvals for Calendar Year 2008 Updated through December 31, 2008 NME New Drug Application (NDA) Approvals: Application Type

Add to Reading List

Source URL: www.fda.gov

Language: English
125New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals As of December 31, 2012 Selection Criteria: User Response: Start Date: [removed]End Date: [removed]

New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals As of December 31, 2012 Selection Criteria: User Response: Start Date: [removed]End Date: [removed]

Add to Reading List

Source URL: www.fda.gov

Language: English
126Janssen Pharmaceutical Companies Product Due Date Status Description of Commitment or Requirement

Janssen Pharmaceutical Companies Product Due Date Status Description of Commitment or Requirement

Add to Reading List

Source URL: www.janssen.com

Language: English - Date: 2014-07-31 20:38:04
127HIGHLIGHTS OF PRESCRIBING INFORMATION[removed]DOSAGE FORMS AND STRENGTHS[removed]These highlights do not include all the information needed to •

HIGHLIGHTS OF PRESCRIBING INFORMATION[removed]DOSAGE FORMS AND STRENGTHS[removed]These highlights do not include all the information needed to •

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-07-07 17:17:35
128HIGHLIGHTS OF PRESCRIBING INFORMATION[removed]DOSAGE FORMS AND STRENGTHS[removed]These highlights do not include all the information needed to •

HIGHLIGHTS OF PRESCRIBING INFORMATION[removed]DOSAGE FORMS AND STRENGTHS[removed]These highlights do not include all the information needed to •

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-08-30 08:36:08
129HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NUCYNTA® safely and effectively. See full prescribing information for NUCYNTA®. NUCYNTA® (tapentadol) immediate-r

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NUCYNTA® safely and effectively. See full prescribing information for NUCYNTA®. NUCYNTA® (tapentadol) immediate-r

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-11-01 16:25:04
130Microsoft Word - Tapentadol_ ERTabs_200533_RC09-10.doc

Microsoft Word - Tapentadol_ ERTabs_200533_RC09-10.doc

Add to Reading List

Source URL: www.fda.gov

Language: English